Intuitive Surgical Global Regulatory Footprint: da Vinci & Ion

An FDA regulatory and commercial footprint dossier of Intuitive Surgical, mapping da Vinci and Ion clearances, product codes, and global market access.

Executive Summary

What does Intuitive Surgical's medical-device regulatory footprint look like, including the FDA 510(k) clearance history of da Vinci and Ion, the applicable product codes, and worldwide market access?

Intuitive Surgical (NASDAQ: ISRG) is the global leader in robotic-assisted surgery, with an FDA clearance genealogy built on two platforms: the da Vinci surgical system (product code NAY, 21 CFR 876.1500, Class II endoscope-and-accessories / computer-controlled surgical instrument) cleared across the Si, Xi, X, SP and now da Vinci 5 generations, and the Ion Endoluminal System (product code EOQ, 21 CFR 874.4680, Class II bronchoscope), first cleared in 2019. Recent milestones include the da Vinci 5 cardiac clearances (announced January 22, 2026), da Vinci SP expanded indications for inguinal hernia, cholecystectomy, and appendectomy (December 10, 2025), and FDA clearance of AI and advanced-imaging software for Ion (October 8, 2025). Worldwide, Intuitive placed 1,721 systems in 2025 (870 da Vinci 5, 107 SP, 195 Ion) and reached 2025 revenue of $10.1 billion (up 21% year over year), with Ion installed in more than 900 hospitals across 10 countries as of June 30, 2025.

What FDA product codes and classification regulations govern da Vinci and Ion?

To understand Intuitive Surgical's regulatory framework, one must examine the specific product codes and classification regulations established by the U.S. FDA. The company's portfolio is structurally split into two primary product codes, each corresponding to a distinct medical specialty, classification panel, and regulation number.

1. Product Code NAY: System, Surgical, Computer Controlled Instrument

The da Vinci surgical system family is regulated under product code NAY. This code falls under the Gastroenterology-Urology devices panel and is classified under 21 CFR 876.1500 (Endoscope and accessories).

Device Class: Class II (Special Controls)
Definition: An endoscope-and-accessories or computer-controlled surgical instrument designed to assist surgeons in the placement and manipulation of surgical instruments during minimally invasive procedures.
Special Controls: Under FDA guidelines, devices registered under product code NAY must comply with rigorous special controls, including extensive biocompatibility testing (ISO 10993-1), electromagnetic compatibility (IEC 60601-1-2), software verification and validation (IEC 62304), usability engineering (IEC 62366), and comprehensive human factors testing.

A deeper look at the FDA product code NAY surgical robotics clearances shows how this classification governs multi-port and single-port robotic platforms, establishing the standard for computerized surgical assistance.

2. Product Code EOQ: Bronchoscope, Flexible or Rigid, and Accessories

The Ion Endoluminal System, which is Intuitive's flexible robotic catheter platform designed for peripheral lung biopsy, is regulated under product code EOQ. This code falls under the Ear, Nose, and Throat (ENT) devices panel and is classified under 21 CFR 874.4680 (Bronchoscope, flexible or rigid, and accessories).

Device Class: Class II (Special Controls)
Definition: An instrument used to examine the trachea and bronchi, and to perform diagnostic and therapeutic procedures within the airway. In the case of Ion, the system consists of a computer-controlled catheter guide, a planning software workstation, and associated biopsy instruments.
Special Controls: Similar to the NAY code, EOQ devices require extensive mechanical performance testing, accuracy verification of the robotic articulation, software safety analysis, and clinical evaluation to prove that the device can navigate tortuous bronchial airways without causing pneumothorax or airway perforation.

System Family	Primary Product Code	Regulation Number	FDA Classification Panel	Device Class	Regulatory Pathway
da Vinci (Standard, S, Si, Xi, X, 5)	NAY	21 CFR 876.1500	Gastroenterology-Urology	Class II	510(k)
da Vinci SP (Single Port)	NAY	21 CFR 876.1500	Gastroenterology-Urology	Class II	510(k)
Ion Endoluminal System	EOQ	21 CFR 874.4680	Ear, Nose, and Throat	Class II	510(k)

FDA Special Controls Requirements for Robotic Surgery Platforms

Because both product codes NAY and EOQ are classified as Class II devices with Special Controls, manufacturers cannot rely on basic General Controls to secure marketing clearance. The FDA enforces specific guidelines that must be addressed in the 510(k) submission.

1. Software Verification and Validation (IEC 62304)

Robotic surgical systems are software-driven capital equipment. Under IEC 62304, the software is typically designated as Class C (highest software risk level), where software failure could result in death or serious injury. Intuitive must demonstrate:

Rigorous unit-level and system-level validation.
Comprehensive cybersecurity threat modeling.
"Unresolved anomalies" logs with safety justifications for any non-critical open bugs.

2. Biocompatibility (ISO 10993-1)

Surgical instruments that contact patient tissue, blood, or mucosal surfaces must undergo biocompatibility assessment. Under ISO 10993-1, instruments like the EndoWrist line require testing for:

Cytotoxicity, sensitization, and intracutaneous reactivity.
Acute systemic toxicity and subchronic toxicity (for extended-contact instruments).
Hemocompatibility (for cardiovascular indications).

3. Electromagnetic Compatibility and Electrical Safety (IEC 60601-1-2)

Robotic consoles and arms operate in high-energy operating rooms alongside electrosurgical units (ESUs), ventilators, and patient monitors. Compliance with the IEC 60601-1 family ensures that:

The system does not emit electromagnetic interference that disrupts other life-critical equipment.
The system is immune to incoming electrical disturbances, preventing unexpected robotic arm movement or video feed dropouts.

4. Usability and Human Factors Engineering (IEC 62366)

Robotic systems introduce complex user interfaces (the surgeon's console, patient cart setup, sterile draping, emergency manual release). Usability testing must prove that:

Operating room staff can safely and rapidly perform emergency undocking (e.g., in the event of patient cardiac arrest).
The surgeon's console controls are intuitive and do not lead to execution errors.
Critical alarms (force limits exceeded, catheter disconnection) are highly visible and clear.

What is the 510(k) clearance genealogy of the da Vinci surgical system family?

The history of the da Vinci system is a case study in incremental regulatory clearances. Rather than seeking a Premarket Approval (PMA) for each generation, Intuitive has successfully utilized the 510(k) pathway by leveraging its own previous models as predicates. This clearance genealogy stretches back more than two decades.

The Origin: Original da Vinci (Standard)

The foundational clearance for the standard da Vinci system was granted under K990144 in 2000. It was cleared for laparoscopic surgical procedures, establishing the initial baseline for "computer-controlled" surgery. This system consisted of a surgeon's console, a patient-side cart with three robotic arms, and a 3D visualization system.

The Second Generation: da Vinci S

Cleared in December 2005 under K050369 and expanded under K063220 and K081207 (December 2008), the da Vinci S system introduced a fourth robotic arm, high-definition (HD) visualization, and a streamlined setup workflow. The K081207 clearance was critical as it finalized the standard product code NAY definition, linking the modern da Vinci S (model IS2000) to its predecessors and expanding the indicated use cases.

The High-Definition Era: da Vinci Si

In 2009, the FDA cleared the da Vinci Si system under K083234. The Si generation focused on dual-console capability (allowing two surgeons to collaborate or train), upgraded HD 3D visualization, and integration of advanced third-party energy and stapling tools.

The Modern Workhorse: da Vinci Xi and da Vinci X

The launch of the da Vinci Xi under K133866 in April 2014 was a major architectural redesign. It replaced the fixed patient cart with a boom-mounted design capable of rotating to access any quadrant of the abdomen without moving the patient cart. It also standardized the use of 8mm instruments. In 2017, the da Vinci X was cleared under K170731. Designed as a lower-cost entry point, the X system utilized the same surgeon's console and instruments as the Xi but mounted them on the older, non-boomed da Vinci Si style patient cart.

The Next Generation: da Vinci 5

The da Vinci 5 system received its primary clearance under K233298 in March 2024. Building on the Xi architecture, the da Vinci 5 introduced force-feedback technology, redesigned console controls, and integrated clinical calculators. On January 22, 2026, Intuitive announced the FDA clearance of da Vinci 5 for cardiac procedures, expanding its reach into cardiothoracic surgical suites.

da Vinci SP: Single-Port Regulatory Strategy and Expanded General Surgery Indications

The da Vinci SP (Single Port) represents a distinct branch in the NAY genealogy. Cleared initially under K173805 in May 2018, the SP system allows the camera and three articulating instruments to emerge from a single 25mm cannula.

The Labeling Expansion Strategy

Because single-port access is geometrically distinct from multi-port access, the FDA initially restricted the SP system's labeling to narrow indications where surgical access is naturally limited (e.g., urology and transoral otolaryngology). To expand into general surgery, Intuitive had to compile clinical data to demonstrate that the single-port configuration does not increase tissue trauma or patient risk.

The General Surgery Expansion — K252069 (Announced December 10, 2025)

On December 10, 2025, Intuitive announced an FDA 510(k) clearance (K252069, clearance letter dated December 2, 2025) that represented a major expansion of the da Vinci SP indication labeling into general surgery:

Inguinal Hernia Repair: Cleared for both unilateral and bilateral repairs.
Cholecystectomy: General gallbladder removal.
Appendectomy: Routine removal of the appendix.

These general surgery clearances position the SP system to compete directly in high-volume, outpatient-adjacent surgical procedures, significantly increasing the utilization rate of installed SP systems.

The Nipple-Sparing Mastectomy Clearance — K252675 (December 15, 2025)

Later the same month, the FDA granted 510(k) K252675 (clearance letter dated December 15, 2025), adding nipple-sparing mastectomy (NSM) to the da Vinci SP (Model SP1098) indications — a major aesthetic and oncological clearance allowing single-port access through a discreet lateral incision. The K252675 submission relied on prospective randomized clinical-trial data demonstrating substantial equivalence to open NSM, rather than on new device hardware.

The Ion Endoluminal System represents Intuitive's expansion outside of abdominal and thoracic cavity surgeries into diagnostic pulmonology. Ion is a catheter-based system that navigates through the peripheral airways of the lung to locate and biopsy suspicious nodules.

The Regulatory Pathway

Unlike the da Vinci, which was established early under the Gastroenterology-Urology panel, the Ion system operates under the ENT panel with product code EOQ (21 CFR 874.4680). The initial clearance for the Ion system (Model IF1000) was granted under K182286 in February 2019. The system was cleared for diagnostic lung biopsy.

AI and Advanced Imaging Software Integration (October 8, 2025)

On October 8, 2025, Intuitive received FDA clearance for a major software update to the Ion system, integrating artificial intelligence and advanced digital imaging algorithms. This update allows the planning software to generate real-time navigational corrections, compensating for CT-to-body divergence (the discrepancy between the static pre-operative CT scan and the dynamic shape of the lung during bronchoscopy).

510(k) Clearance K252528 (September 5, 2025)

Leading up to the software launch, the FDA cleared K252528 on September 5, 2025. This clearance approved mechanical hardware and tool modifications for the Ion flexible catheter and sheath, facilitating smoother navigation and compatibility with newer, high-definition peripheral visualization probes.

Global Market Access: Navigating EU MDR, Japan PMDA, and China NMPA

Securing FDA clearance is only the first step in Intuitive's global commercial strategy. Each major market requires navigating specific regulatory hurdles, local reimbursement structures, and capital equipment procurement controls.

1. European Union: The MDR (Regulation (EU) 2017/745) Transition

Under the old Medical Devices Directive (MDD), surgical robots were classified as Class IIb. The transition to the Medical Device Regulation (EU) 2017/745 (MDR) has increased the clinical evidence requirements:

Clinical Evaluation Reports (CERs): Under EU MDR Article 61, Intuitive must supply continuous, prospective clinical data for every cleared indication.
Notified Body Review: Because of limited Notified Body capacity in Europe, expanding indications or bringing new systems (like da Vinci 5) to the EU market requires navigating long review queues.
Symbol and Representative Compliance: Labeling must comply with recent guidelines, including authorized representative markings (e.g., the transition from EC REP to EU REP as outlined in the EU authorized representative EC REP guide).

2. Japan: PMDA Approvals and National Health Insurance (NHI) Reimbursement

Japan is a key market, but the Pharmaceuticals and Medical Devices Agency (PMDA) enforces unique evaluation guidelines for robotic systems.

Shonin Approval: Capital systems must undergo rigorous local safety reviews.
NHI Reimbursement Categories: In Japan, commercial success depends on whether the Ministry of Health, Labour and Welfare (MHLW) grants specific reimbursement codes for robotic procedures. Between 2018 and 2024, Japan expanded NHI coverage to more than 29 robotic procedures (including gastrectomy, lobectomy, and hysterectomy), driving rapid installed-base growth.
PMDA Electronic Submissions: Navigating Japan's transition to newer electronic formats (e.g., PMDA eCTD v4.0 medical device submission guide) is a critical operational focus for Intuitive's local regulatory team.

3. China: NMPA Registration and Government Procurement Quotas

The National Medical Products Administration (NMPA) regulates surgical robots under Class III (highest risk category for China), requiring local clinical trials or extensive clinical evaluation reports matching Chinese demographics.

The Quota System: In China, hospitals cannot purchase Class A or Class B large medical equipment (such as the da Vinci) without a government-issued procurement quota. The National Health Commission (NHC) releases multi-year quota plans (e.g., the 14th Five-Year Plan), which dictate exactly how many surgical robots can be imported or sold.
Localization Push: To bypass quota limitations and secure preferential government bidding, Intuitive established a joint venture (Fosun Intuitive) to manufacture systems locally in Shanghai, adapting to China's strict domestic procurement preferences.

Safety Records, Recalls, and MAUDE Reporting Dynamics

As robotic systems become more common, their safety profiles are heavily documented in post-market surveillance databases. Understanding these dynamics is critical for competitive analysis.

MAUDE Database Concentration

Because surgical robots are complex systems containing hundreds of sensors, electronic boards, mechanical gears, and software modules, they naturally generate a high volume of Medical Device Reports (MDRs) in the FDA's Manufacturer and User Facility Device Experience (MAUDE) database.

Malfunction vs. Injury: The vast majority of reported events for product code NAY are classified as "Malfunctions" (e.g., system error codes, instrument articulation faults, or minor software lag). These reports are required under FDA post-market surveillance guidelines, even if the surgeon simply restarted the console and completed the case.
Reporting Bias: High-volume facilities that utilize robots daily have systematic reporting programs that capture every minor technical fault, creating a high volume of reports that does not necessarily correlate with patient injury.

Historical Recall Patterns

Most da Vinci recalls are classified as Class II (low risk of serious injury or death) and typically involve:

Labeling updates for specific instruments (clarifying reprocessing/sterilization steps).
Software patches to address specific edge-case error codes.
Hardware inspections (e.g., checking instrument arm tension or cables).

Surgical robotics manufacturers must manage these recalls through structured Field Safety Corrective Actions (FSCAs), coordinating closely with hospital risk managers to apply software patches or swap out affected instrument lots without interrupting surgical schedules.

What is Intuitive's worldwide installed base and 2025 system placement footprint?

The financial strength of Intuitive Surgical is directly tied to its active global installed base. Unlike typical capital-equipment medical device firms, Intuitive utilizes a "razor-and-blade" commercial model, where every installed system generates ongoing recurring revenue through instrument sales, accessory kits, and service contracts.

2025 System Placements

According to full-year 2025 commercial disclosures, Intuitive placed 1,721 systems worldwide in 2025, representing a strong increase over the previous year. This placement activity was driven heavily by the global launch of the da Vinci 5:

da Vinci 5 Placements: 870 systems
da Vinci SP Placements: 107 systems
Ion Placements: 195 systems
Multi-Port Legacy (Xi/X) Placements: 549 systems

This commercial push helped lift Intuitive's total full-year 2025 revenue to $10.1 billion, representing a 21% growth year-over-year compared to 2024.

Global Installed Base Footprint

At the end of 2021, Intuitive's installed base stood at 6,730 da Vinci systems (geographically distributed as 4,139 in the US, 1,199 in Europe, 1,050 in Asia, and 342 in the rest of the world). Following four years of active placements through 2022–2025, the total active installed base has expanded significantly, crossing the 10,000-system threshold.

For the Ion platform, as of June 30, 2025, more than 900 Ion systems were installed in hospitals across 10 countries, demonstrating rapid international adoption of the bronchoscopy system outside the United States.

How does Intuitive's regulatory footing compare with Medtronic Hugo and J&J Ottava?

Intuitive's long-standing monopoly is facing its most significant challenge as major medtech diversified firms bring competing robotic platforms to market. The principal competitors are the Medtronic Hugo and the Johnson & Johnson MedTech Ottava.

Medtronic Hugo RAS System

The Medtronic FDA device footprint indicates a massive presence across Class III cardiac and spinal markets, but Medtronic has historically lagged in abdominal robotics. That changed in December 2025 when the FDA granted 510(k) clearance (K250725, announced December 3, 2025) for the Medtronic Hugo Robotic-Assisted Surgery (RAS) system for urological procedures.

Regulatory Approach: Medtronic Hugo utilizes a modular cart design (each arm is on its own separate mobile cart) compared to the single-cart boom design of the da Vinci Xi. Notably, the Hugo RAS System was cleared under its own distinct product code SCV (Modular electromechanical surgical system, 21 CFR 878.4964) — separate from Intuitive's NAY lineage — rather than as a da Vinci predicate.
Indication Gaps: While cleared in Europe under CE mark since 2021 for gynecology, urology, and general surgery, Hugo's U.S. FDA clearance remains restricted to urology as of early 2026. This gives Intuitive a substantial clinical indication advantage, especially with the recent da Vinci 5 cardiac and da Vinci SP general surgery expansions.

Johnson & Johnson MedTech Ottava

J&J's Ottava system represents a different architectural philosophy. It integrates the robotic arms directly into the operating table structure, saving floor space.

Regulatory Approach: Unlike Hugo and da Vinci, J&J is pursuing the Premarket Approval (PMA) and clinical trial route for Ottava to secure broad initial indications. J&J's dossier is mapped out in the Johnson & Johnson MedTech global registrations dossier format.
Timeline Gaps: Ottava is expected to enter clinical trials in the United States in late 2026, meaning a commercial launch is unlikely before 2028. This leaves a multi-year window where Intuitive's da Vinci 5 can saturate the multi-port market.

The Regulatory Moat

Intuitive's primary advantage is not just the hardware, but its extensive regulatory "moat." With over 20 years of clearance history, Intuitive has established a massive library of cleared instruments (staplers, energy devices, retractors, scissors) under product code NAY. Competitors like Medtronic and J&J must clear each equivalent instrument separately, a process that requires substantial biocompatibility, reliability, and human factors validation.

Additionally, understanding the general robotic surgery device regulatory pathway is critical for analyzing how these new entrants navigate FDA special controls and EU MDR requirements.

Furthermore, general strategic trends can be explored in the surgical robotics M&A and funding landscape to understand how smaller robotic start-ups are positioned relative to the dominant players.

Frequently Asked Questions (FAQs)

Is the da Vinci surgical system cleared by 510(k) or approved by PMA?

The entire da Vinci surgical system family is cleared through the FDA's 510(k) premarket notification pathway. Because the system is classified under 21 CFR 876.1500 as a Class II Gastroenterology-Urology endoscope and accessory, it does not require a Premarket Approval (PMA) application, although it must comply with strict special controls.

What FDA product code applies to the da Vinci surgical system and to Ion?

The da Vinci surgical system is registered under product code NAY (System, Surgical, Computer Controlled Instrument). The Ion Endoluminal System is registered under product code EOQ (Bronchoscope, flexible or rigid, and accessories).

When did the FDA clear da Vinci 5 for cardiac procedures?

The FDA clearance for cardiac procedures on the da Vinci 5 system was announced by Intuitive Surgical on January 22, 2026. This clearance expanded the initial multi-port indications granted in March 2024.

How many da Vinci and Ion systems has Intuitive placed worldwide as of 2025?

In 2025 alone, Intuitive placed 1,721 systems (870 da Vinci 5, 107 da Vinci SP, 195 Ion, and 549 legacy Xi/X systems). This brought the total global installed base of da Vinci systems to well over 10,000 active systems, with the Ion system installed in more than 900 hospitals globally as of June 30, 2025.

What are the regulatory implications of the December 2025 da Vinci SP clearances?

December 2025 brought two separate da Vinci SP expansions. K252069 (announced December 10, 2025) added the general surgeries — inguinal hernia repair, cholecystectomy, and appendectomy. K252675 (clearance letter dated December 15, 2025) then added nipple-sparing mastectomy. Previously, the SP system was limited primarily to narrow urology, colorectal, and transoral procedures. Together these clearances position the single-port SP platform to compete directly in the high-volume general surgery market.

Regulatory Compliance and Disclaimers

This dossier is compiled for educational and competitive-intelligence purposes only based on public FDA disclosures and corporate filings. It does not constitute regulatory, legal, or strategic advisory services for any medical device manufacturer. For official classification and regulatory guidelines, consult the FDA Product Classification Database or a certified regulatory affairs professional.